Vertex Pharmaceuticals, Inc (NASDAQ:VRTX) does about 1.72M shares in volume on a normal day but saw 1286958 shares change hands in the recent trading day. The company now has a market cap of 115.95B USD. Its current market price is $451.52, marking an increase of 1.20% compared to the previous close of $446.15. The 52 week high reached by this stock is $519.88 whilst the lowest price level in 52 weeks is $377.85. The script in recent trading has seen the stock touch a high of $545 and a low of $400.
16 analysts observing the Vertex Pharmaceuticals, Inc (VRTX) stock have set the 12-month price targets for the company’s shares at between $400 and $545. The consensus objective for the share price is $507.96, suggesting that the stock has a potential upside of 11.11% over the period. The median price target is 1.41% away from the current levels at $458.
FactSet Research has provided data showing that 16 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 11 analysts have rated it as a buy and 5 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Moderate Buy the stock.
Leerink Partners also downgraded the stock to “Market Perform” from Outperform on May 06, 2025 at a price target of $503. Cantor Fitzgerald resumed its price target at $535.
The current price level is 2.28%, -2.84%, and -3.12% away from its SMA20, SMA50, and SMA200 respectively, with the VRTX price moving above the 50-day SMA on current market day. Vertex Pharmaceuticals, Inc (VRTX) stock is up 1.13% over the week and 6.24% over the past month. Its price is 12.12% year-to-date and -7.00% over the past year.
Its 12-month price target is $458. To reach the target analysts have set, the stock logically needs to grow 11.11 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $400, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $545.
Outstanding shares total 256.97M with insiders holding 0.16% of the shares and institutional holders owning 97.90% of the company’s common stock. The company has a return on investment of -5.45% and return on equity of -5.64%. The forward price to earnings ratio is 21.70. The beta has a value of 0.42. Price to book ratio is 7.03 and price to sales ratio is 10.50.
